ClinicalTrials.gg
RecruitingNCT07008755Updated Jun 6, 2025

Clinical Trial of Pegylated Interferon α-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .

An interventional study of Peginterferon α-2b injection and Peginterferon α-2b injection in HFMD, sponsored by Zhengzhou Children's Hospital, China. Recruiting at 5 sites in China. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Zhengzhou Children's Hospital, China · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2024, registered May 2025).
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
1 Year to 6 Years
Sex
All
01

Study summary

This is a multicenter clinical trial investigating the safety and efficacy of inhaled Peginterferon α-2b at different doses, in combination with supportive care, for the treatment of patients with hand, foot, and mouth disease (HFMD) of ordinary type. The trial aims to enroll 90 patients with HFMD. Eligible subjects will be randomly assigned to receive either supportive care + Peginterferon α-2b mcg or supportive care + Peginterferon α-2b 90 mcg, administered on days 1 and 3. The study period includes a 3-day screening phase and a 5-7 day inpatient visit period. The results of this trial will be used to evaluate safety and efficacy.

02

Conditions studied

  • HFMD

Keywords

  • Peginterferon α-2b injection
  • HFMD
03

In context

Lead sponsor

Zhengzhou Children's Hospital, China is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-1. Age: 1 year of age ≤ Age ≤ 6 years of age. 2.Gender: Both male and female. 3.Clinical symptoms/signs: Manifesting as common type HFMD (Stage 1, rash stage), with fever or rash symptoms first occurring within 72 hours prior to the signing of the form.

4.Informed consent: Guardians understand and sign the informed consent form (if the guardian is the parent, both parents must sign).

Exclusion criteria

Exclusion Criteria:

  • (1) Severe or Critical HFMD Presentation at Enrollment

    1. Manifesting as severe HFMD (Stage 2, neurological involvement phase)
    2. Manifesting as critical HFMD (Stage 3 or 4, cardiopulmonary failure phase) with any of:

      Brainstem encephalitis, encephalomyelitis, or meningitis,Neurogenic pulmonary edema or respiratory failure requiring mechanical ventilation,Shock or circulatory collapse.

    3. Concurrent multi-organ failure requiring ICU monitoring

      (2) Allergy History and Treatment History

    <!-- -->

    1. Received interferon, ribavirin, acyclovir, ganciclovir, or vidarabine monophosphate within 30 days prior to screening or current use
    2. Received immunoglobulin or therapy within 30 days prior to screening or current use
    3. Known to interferon or its components, or other allergies contraindicating participation
    4. Use of other drugs within 3 months or 5 half-lives (whichever is longer) prior to screening, or current participation in medical device trials

      (3) Medical History

    <!-- -->

    1. Congenital heart disease, severe malnutrition, immune dysfunction, asthma, or other severe systemic diseases
    2. Active , , , or Treponema pallidum infection
    3. History of malignant tumors (current or prior)
    4. History of epilepsy, neurological/psychiatric disorders, or relevant family history

      (4) Clinical Parameters: Resting respiratory rate >40 breaths/min,Heart rate >160 bpm

      (5) Other Considerations: Any condition deemed by investigators to render participation medically inadvisable

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Peginterferon α-2b 45 mcg dose group

    Drug: Peginterferon α-2b injection

  • Experimental
    Peginterferon α-2b 90 mcg dose group

    Drug: Peginterferon α-2b injection

Interventions

  • During the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 45 μg per administration, to be delivered on Day 1 and Day 3.

  • CoDuring the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 90 μg per administration, to be delivered on Day 1 and Day 3.

06

What researchers measure

Primary outcomes

  1. Median time to resolution of fever

    Time frame: Day5-7.

  2. Median time to resolution of skin rash

    Time frame: Day5-7.

  3. Median time to resolution of oral ulcers

    Time frame: Day5-7.

  4. Median time to resolution of feeding difficulties

    Time frame: Day5-7.

Secondary outcomes

  1. Proportion of patients with complete recovery of fever

    Time frame: Day 3

  2. Proportion of patients with complete recovery of fever

    Time frame: Day 5

  3. Proportion of patients with complete recovery of rash

    Time frame: Day 3

  4. Proportion of patients with complete recovery of rash

    Time frame: Day 5

  5. Proportion of patients with complete recovery of oral ulcers

    Time frame: Day 3

  6. Proportion of patients with complete recovery of oral ulcers

    Time frame: Day 5

  7. Proportion of patients with complete recovery of feeding difficulties

    Time frame: Day 3

  8. Proportion of patients with complete recovery of feeding difficulties

    Time frame: Day 5

  9. Proportion of patients showing improvement in fever

    Time frame: Day 3

  10. Proportion of patients showing improvement in fever

    Time frame: Day 5

  11. Proportion of patients showing improvement in rash

    Time frame: Day 3

  12. Proportion of patients showing improvement in rash

    Time frame: Day 5

  13. Proportion of patients showing improvement in oral ulcers

    Time frame: Day 3

  14. Proportion of patients showing improvement in oral ulcers

    Time frame: Day 5

  15. Proportion of patients showing improvement in feeding difficulties

    Time frame: Day 3

  16. Proportion of patients showing improvement in feeding difficulties

    Time frame: Day 5

  17. Proportion of patients developing pulmonary edema

    Time frame: Day1-7

  18. Proportion of patients developing myocarditis

    Time frame: Day1-7

  19. Proportion of patients developing respiratory failure

    Time frame: Day1-7

  20. Proportion of patients developing circulatory failure

    Time frame: Day1-7

  21. Proportion of patients developing meningoencephalitis

    Time frame: Day1-7

  22. Proportion of patients achieving viral nucleic acid negativity

    Time frame: Day 3

  23. Proportion of patients achieving viral nucleic acid negativity

    Time frame: Day 5

07

Study locations

5 of 5 sites recruiting
  • Xindu District People's Hospital of Chengdu
    Chengdu, China
    Recruiting
    • Jingrong Yang · Contact
  • The Seventh People's Hospital of Liangshan Yi Autonomous Prefecture
    Liangshan, China
    Recruiting
    • Min Fang · Contact
  • Henan Children's Hospital (Zhengzhou Children's Hospital)
    Zhengzhou, China
    Recruiting
    • Fang Wang · Contact
  • Zhengzhou People's Hospital
    Zhengzhou, China
    Recruiting
    • Chao Liu · Contact
  • Ziyang Central Hospital
    Ziyang, China
    Recruiting
    • Jing Tang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Oct 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2025
First posted
Jun 6, 2025
StartActual
Jul 31, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07008755
Lead sponsor
Zhengzhou Children's Hospital, China
Responsible party
Fang Wang (Chief physician, Zhengzhou Children's Hospital, China) — Principal investigator
First posted
Jun 6, 2025
Start date
Jul 31, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 6, 2025

Study contacts

Fang Wang
Contact
13783637576@139.com
13783637576
Fang Wang
principal investigator · Henan Children's Hospital (Zhengzhou Children's Hospital)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion